Emcure Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Emcure Pharmaceuticals Ltd reported a 4.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.6%.
• Its expenses for the quarter were up by 6.4% QoQ and 15.8% YoY.
• The net profit increased 5.3% QoQ and increased 23.6% YoY.
• The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 12.84 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

## Company Overview
Emcure Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry. The company focuses on manufacturing and marketing a wide range of pharmaceutical products, including formulations across various therapeutic segments. Emcure is involved in the development of both generic and innovative drugs, catering to the healthcare needs across numerous markets. As of the data available up to October 2023, there are no specific recent developments mentioned regarding Emcure Pharmaceuticals, so the focus remains on their core business activities in the pharmaceutical sector.

## Revenue
For the fourth quarter of fiscal year 2026 (Q4FY26), Emcure Pharmaceuticals reported a total income of ₹2473.70 crores, which reflects an increase of 4.6% compared to the previous quarter (Q3FY26) and a 16.6% increase year-over-year when compared to the fourth quarter of fiscal year 2025 (Q4FY25). This growth in revenue indicates a strong upward trajectory in the company's financial performance over the past year. The sequential growth from Q3FY26 to Q4FY26 highlights a continued positive trend in revenue generation for the company.

## Profitability
The company's profitability metrics for Q4FY26 demonstrate a robust performance. Emcure Pharmaceuticals recorded a profit before tax of ₹341.18 crores, marking an 8.7% increase from the previous quarter and a significant 30.9% increase year-over-year. After accounting for taxes, the profit after tax stood at ₹243.73 crores, which is a 5.3% increase QoQ and a 23.6% increase YoY. The earnings per share also experienced growth, rising to ₹12.84 in Q4FY26, up 5.6% from the previous quarter and 28.8% from the same quarter last year.

## Operating Metrics
Reviewing the expense figures, Emcure Pharmaceuticals reported total expenses of ₹2142.82 crores in Q4FY26. This represents a 6.4% increase from Q3FY26 and a 15.8% increase compared to Q4FY25. The tax expenses for the company increased by 18.2% QoQ and 53.7% YoY, indicating a higher effective tax rate or increased profitability impacting tax liabilities. These operating metrics reflect the company's scaling operations and the associated costs. The overall financial ratios, such as the P/E ratio and other specific financial metrics, are not calculated here due to the absence of necessary additional data.